cooperative-group
People who lead or represent a cooperative trials group. 17 records carry it: 17 people.
Related tags
17 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Aimery de Gramont Head of Medical Oncology, Institut Hospitalier Franco-Britannique; Founder, GERCOR and ARCAD Invented the FOLFOX regimen that anchors colorectal chemotherapy and founded the GERCOR and ARCAD trial groups. | Colorectal cancer | none | colorectal, chemotherapy | ||
Andreas du Bois Director of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte; Chair, AGO Study Group · Kliniken Essen-Mitte Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer. | Ovarian cancer | none | ovarian, surgery | ||
Bradley J. Monk Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment. | Cervical cancer, Ovarian cancer | none | cervical, ovarian | ||
Christiane Pott President (Praesidentin) of the German Lymphoma Alliance · German Lymphoma Alliance Kiel professor of medicine who serves as President of the German Lymphoma Alliance, the umbrella body for German lymphoma study groups, alongside co-president Georg Lenz. | none | none | leadership, clinician-scientist, haematology | ||
Ignace Vergote Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT · UZ Leuven / Leuven Cancer Institute Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer. | Ovarian cancer, Cervical cancer | none | ovarian, cervical, adc | ||
Jeffrey S. Dome Senior Vice President, Center for Cancer and Blood Disorders, Children's National Hospital, Washington DC · Children's National Hospital Led the COG renal tumour committee that used biology to tailor Wilms tumour treatment. | Wilms tumour | none | paediatric, wilms-tumor | ||
Kara M. Kelly Chair of Pediatric Oncology, Roswell Park Comprehensive Cancer Center; Division Chief, Pediatric Hematology/Oncology, University at Buffalo · Roswell Park Comprehensive Cancer Center Leads the COG Hodgkin lymphoma committee and the trials bringing brentuximab and nivolumab to children with the disease. | Hodgkin lymphoma | none | paediatric, hodgkin | ||
Linda Mileshkin Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result. | Cervical cancer, Cancer of unknown primary | none | cervical, australia | ||
Martin Dreyling Professor of Medicine and Head of the Lymphoma Program, LMU University Hospital Munich; Chair, European MCL Network · LMU Klinikum München Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients. | Mantle cell lymphoma | none | lymphoma, mantle-cell | ||
Nicola Gökbuget Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt · University Cancer Center Frankfurt (UCT) Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL. | Acute lymphoblastic leukaemia | none | all, mrd | ||
Richard M. Stone Chief of Staff and Director of Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Led RATIFY, the trial that made midostaurin the first targeted therapy added to induction chemotherapy for AML. | Acute myeloid leukaemia | none | aml, flt3 | ||
Rolf A. Stahel President, ETOP IBCSG Partners Foundation; Emeritus Professor of Oncology, University of Zurich · ETOP IBCSG Partners Foundation Founded the European Thoracic Oncology Platform and leads the merged ETOP IBCSG academic trials foundation. | Non-small-cell lung cancer, Mesothelioma | none | thoracic, europe | ||
Ruth Ladenstein Professor of Paediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna · St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI) Chaired the SIOPEN HR-NBL1 trial, the largest neuroblastoma trial ever, which set European standards for high-risk disease. | Neuroblastoma | none | paediatric, neuroblastoma | ||
Sébastien Armanet Directeur Général (Director General) of ARCAGY-GINECO · ARCAGY-GINECO Director General who runs the operational team of ARCAGY-GINECO, the French non-profit academic research group for gynaecological and metastatic breast cancers. | Ovarian cancer, Endometrial cancer, Cervical cancer | none | leadership, clinical-trials | ||
Sirpa Leppä Chairperson, Nordic Lymphoma Group · Nordic Lymphoma Group Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries. | Diffuse large B-cell lymphoma, Hodgkin lymphoma | none | leadership, clinician-scientist, lymphoma | ||
Stefan S. Bielack Head of Paediatric Oncology, Klinikum Stuttgart Olgahospital; Chair, Cooperative Osteosarcoma Study Group · Klinikum Stuttgart / Olgahospital Leads the COSS group and co-led EURAMOS-1, the largest osteosarcoma trial ever run. | Osteosarcoma | none | paediatric, osteosarcoma | ||
Stephen P. Hunger Chief, Division of Oncology, Children's Hospital of Philadelphia; Jeffrey E. Perelman Distinguished Chair in Pediatrics · Children's Hospital of Philadelphia Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%. | Acute lymphoblastic leukaemia | none | paediatric, all |
